BerandaROIV • NASDAQ
add
Roivant Sciences Ltd
$23,13
Setelah Jam Perdagangan Normal:(0,00%)0,00
$23,13
Tutup: 16 Jan, 16.56.13 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$23,30
Rentang hari
$22,15 - $23,20
Rentang tahun
$8,73 - $23,91
Kapitalisasi pasar
16,09Â M USD
Volume Rata-Rata
7,76Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,57Â jt | -64,89% |
Biaya operasional | 129,52Â jt | -34,01% |
Penghasilan bersih | -113,52Â jt | 50,68% |
Margin laba bersih | -7,23Â rb | -40,48% |
Penghasilan per saham | -0,28 | 7,14% |
EBITDA | -291,21Â jt | 12,10% |
Tarif pajak efektif | -4,40% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 4,39Â M | -18,58% |
Total aset | 5,06Â M | -18,42% |
Total liabilitas | 257,14Â jt | -58,92% |
Total ekuitas | 4,81 M | — |
Saham yang beredar | 695,49 jt | — |
Harga terhadap nilai buku | 3,69 | — |
Tingkat pengembalian aset | -14,47% | — |
Tingkat pengembalian modal | -14,87% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -113,52Â jt | 50,68% |
Kas dari operasi | -185,66Â jt | 30,41% |
Kas dari investasi | 120,42Â jt | 103,66% |
Kas dari pembiayaan | 62,59Â jt | 157,38% |
Perubahan kas bersih | -1,45Â jt | 99,96% |
Arus kas bebas | -100,51Â jt | -181,25% |
Tentang
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
CEO
Didirikan
7 Apr 2014
Situs
Karyawan
750
